Faster processes. Same-day assessments. Expert consultations from anywhere.

Tissue preparation for microscopic examination is time-consuming and technique-dependent, resulting in variable quality which complicates diagnostic interpretation by physicians and digital analysis systems.

 

Physical slides also reduce the ability of medical specialists to collectively review the patient’s condition and collaboratively determine the best treatment plan.

our focus

About Applikate

Applikate Technologies is a hardware and software company that has developed the first automated histology platform with integrated digital imaging. Our patented technology stains and images whole samples without the need for physical slicing. The platform automates the pathology workflow, cuts processing time, lowers labor and materials costs, improves image quality, and reduces the risk of misdiagnosis.

Our Mission

Applikate's mission is to modernize pathology with technology that significantly reduces hospital costs, improves medical diagnosis, and enables a faster clinical response to patients.

Our Vision

Applikate envisions a world without the need for physical slides and prohibitively expensive histology equipment and storage.

Our Mission

Applikate's mission is to modernize pathology with technology that significantly reduces hospital costs, improves medical diagnosis, and enables a faster clinical response to patients.

Our Vision

Applikate envisions a world without the need for physical slides and prohibitively expensive histology equipment and storage.

The Applikate Advantage

From over 20 manual steps reduced to 3 simple steps.

The time and cost of producing physical slides constrains the number of slides per patient that a pathologist reviews, limiting the diagnostic information at their disposal.

Immediate visualization of multiple tissue layers

Globally accessible images from software that navigates multiple tissue levels for improved diagnosis and analysis.

Elimination of physical slides

Legacy technologies compensate for physical slide limitations by layering more equipment and steps on an archaic process.

High resolution multiphoton microscopy at depth

The fastest high-resolution multiphoton microscope in the world, sub-micron resolution at depth.

  • Our Patented Pathology Platform:

    Obsoletes wax, microtomes, & microscopes

    By imaging intact, un-embedded tissue biopsies, Applikate's patented pathology technology enables expert human diagnosis within 3 hours of receipt of tissue.

  • Our Increased THROUGHPUT & LOWER COST:

    Eliminates tissue slices, slides, & overtime

    With our technology, hospital pathology departments reduce processing time from 16 hours to less than 3 hours.

  • OUR DISRUPTIVE, SCALABLE TECHNOLOGY:

    Enhances tissue samples, labs, & hospitals

    Applikate introduces a modern, direct-to-digital pathology platform that eliminates physical slides, cuts histotech time by 80 percent, and improves diagnosis.

Our Timeline

Important Milestones

Since 2013, Applikate has been revolutionizing pathology, reducing medical errors, and lowering cost.

2013

Applikate Founded

Torres and Levene establish Applikate Technologies, LLC in New Haven, CT after publishing an innovative approach to clinical histology using unique chemical combinations and advanced microscopy.

2014

First Grant

National Cancer Institute awards Applikate’s first NIH SBIR grant.

2014

Stackstreamer Software

Initial version of Applikate’s Stackstreamer software demonstrates practical, web-based, image navigation of arbitrarily large three-dimensional digital histology data sets.

2015

Proprietary Tissue Processing

Applikate develops proprietary tissue processing method for multiphoton imaging with cost, speed, and quality features enabling clinical use.
2015

NIH Award

Applikate receives NIH SBIR award from National Institute of Biomedical Imaging and Bioengineering.

2016

Article Publication

Published article illustrates unique capabilities of CHiMP for assessment of human renal tissue specimens.

2017

First Proprietary System

Applikate builds first advanced proprietary system for high-speed, high-resolution, multiphoton microscopy of clinical specimens.

2017

Follow-On Grant

Applikate receives follow-on NIH/NCI SBIR grant funding to continue CHiMP development.

2018

First Prototype

Applikate builds first prototype of automated tissue processor for CHiMP that requires no human handling.

2018

First Clinical Study

Applikate Technologies and Yale-New Haven Hospital begin first clinical study using Applikate’s CHiMP platform for prostate cancer patients.

2019

Fourth NIH Award

Applikate awarded fourth NIH/NCI SBIR to explore specialized applications of CHiMP.

2019

Applikate In The Media

Various publications and presentations highlight CHiMP’s potential impact in breast cancer, liver disease, kidney disease, and research histology applications.

2019

NIDDK Grant

Applikate receives grant from National Institute of Diabetes and Digestive and Kidney Diseases for development focused on renal pathology.

2020

Key Patents Granted

U.S. Patent Office grants key patents to Applikate covering various aspects of the CHiMP platform.

2020

Applikate Joins CDL

Applikate joins the Creative Destruction Lab (CDL) business incubator.

2020

Prostate Cancer Diagnosis Study

Published prostate cancer diagnostics study demonstrates viability of CHiMP as a primary diagnostic platform with critical advantages.

2021

CDL Showcase

CDL showcases Applikate at its annual Super Session.

2021

Over-Subscribed Seed Round

Applikate closes over-subscribed seed round and becomes Applikate Technologies, Inc.

2022

Second Clinical Validation Round

Applikate begins second phase of clinical validation studies using CHiMP.

Subscribe to the latest at Applikate:

Applikate Technologies provides an elegant solution to the difficult and time-consuming problems faced by pathologists and their staff. The company’s solution offers a revolutionary approach to histology without requiring new skills, extensive training, or prohibitive costs. This technology has not yet been cleared by FDA for diagnostic use and is currently for Research Use Only.

Company

Scroll to Top
Scroll to Top
 
 
Machine Learning

William Tunstall-Pedoe

Investor, Technology Expert, and Entrepreneur
William Tunstall-Pedoe is an entrepreneur who founded the British voice-assistant company Evi, which was purchased by Amazon in 2012 and became the basis for Amazon Alex and Echo devices. William mentors and invests in innovative startups and has holdings in more than 70 companies.
Icon-linkedin-1 Icon-monitor
 
 

John Turner

Medical Expert, Pathologist, and Business Advisor
John Turner trained as resident and fellow at Duke University University Medical Center receiving his boards in Anatomic, Clinical, and Dermatopathology. A practicing pathologist, he is the HCA/ForwardPathology Solutions Capital Division Medical Director and Chief of the Medical Staff for CJW Medical Center. Dr. Turner is a medical advisor to Applikate.
Icon-linkedin-1 Icon-monitor
 

Andrew Nutter

Investor, Technology Expert, and Entrepreneur
Andrew is the co-founder of Gama, a deep space exploration company. He is an investor in over 60 companies across a range of industries, from synthetic biology to nuclear fusion. Previously, Andrew built Westwing, a publicly listed home and living ecommerce business across Europe, Russia, and Brazil. He is a veteran of Balderton Capital and McKinsey & Company.
Icon-linkedin-1 Icon-twitter-1

 
 

Dick Hamrick

Investor, Physician, Medical Expert, and Business Advisor
Dick Hamrick is a pulmonary/critical care physician with a long history of diverse and broad leadership positions including as a Divisional Chief Medical Officer for HCA. Dr. Hamrick serves as a healthcare consultant and as an advisor/board member for Applikate and several early stage companies.
Icon-linkedin-1 Icon-monitor

Ron Bridges

Investor, Physician, Medical Expert, and Professor
Ron Bridges is a Professor of Medicine and Gastroenterologist at the Cumming School of Medicine, University of Calgary. He has held several senior leadership roles, authored more than 40 papers and is actively involved as a mentor at the Creative Destruction Lab. Ron is an angel investor with an interest in medical devices and health care innovations.
Icon-linkedin-1 Icon-bookmark

Julie Cook

Investor, Information Technology Expert, and Business Advisor

Julie is CIO of Ensemble IP and an investor in Applikate. She has extensive experience managing software development, software implementation, data science, and IT security projects. Previously, she led a Health Information Management (HIM) department; and provided consulting, implementation, and training services as part of the delivery of HIM software to hospitals and clinics worldwide.

Donald Plewes

Investor, Professor, and Medical Device Expert
Donald Plewes is Professor Emeritus from the Department of Medical Biophysics of the University of Toronto. His career has been devoted to research in the physics of medical imaging and has included x-ray imaging, computed tomography, ultrasound, and magnetic resonance imaging with clinical applications. His research proceeds from bench science and clinical trials; and has led to the successful commercialization of advanced technologies for breast screening and magnetic resonance imaging.

Dr. Plewes has published widely, holds numerous patents, and is an investor in and expert advisor to Applikate Technologies.
MSc, Aviation Systems
 
 
 

Chris Hadfield

Investor, Astronaut, and Technology Expert
Chris Hadfield is an engineer, military fighter/test pilot and thrice-flown astronaut, having done two spacewalks and commanded the International Space Station. He is an advisor/director for multiple high-tech companies, and leads the Space stream at the Creative Destruction Lab tech incubator. Chris is a four-time internationally best-selling author, a professor at U Waterloo and online at Masterclass, and has created/hosted TV series with both BBC and National Geographic. Chris is an investor in Applikate Technologies and serves as an advisor to the company.
Icon-linkedin-1 Icon-twitter-1 Icon-monitor

 
Caltech

Eben Olson, Ph.D.

Lead Engineer
Eben Olson, Ph.D. is an Associate Research Scientist in the Department of Laboratory Medicine at Yale University, where he has been a member since 2013. His graduate degree is in Applied Physics with a focus on Biomedical Optics. Eben has been performing research involving development of software tools and methods for processing, visualization, and analysis of large image datasets. He is a core contributor to neural network framework modules in Python and has competed successfully in a number of data science competitions on kaggle.com and drivendata.org. He has extensive experience in electronics, machining, CAD, and optical design, having constructed several advanced multiphoton microscopes including design of control boards, optical element assembly, and embedded control software as well as having written Applikate’s StackStreamer software. In part through management of the engineering and clinical consultants. His primary responsibilities include engineering development, software conversion efforts, technical assessments and performance monitoring, component fabrication, hardware and software systems installations during clinical study, and directing engineering support during data acquisition.
Icon-linkedin-1 Icon-bookmark

Cohort 4 Full Time, Certificate 2019

 

 

 

David Hunt, MBA

Executive Chairman
Dave Hunt is Executive Chairman of Applikate. He is also the CEO and majority shareholder at Ensemble IP. Previously, he owned and led Landon IP, a large professional patent search and analytics company with operating offices in the United States, Japan, United Kingdom, Germany, India, and China. He is an early-stage investor in several medical device and AI-focused companies and led the Seed Series round for Applikate Technologies. He leads the business functions of Applikate and chairs the Board of Directors. He is a graduate of the College of William & Mary (B.A., ‘87, M.B.A, ‘93) and the Harvard Business Analytics Program (’19). Dave speaks English and Japanese.
Icon-linkedin-1 Icon-monitor
 

Michael Levene, Ph.D.

Founder, Co-CEO
Michael Levene pioneered the combination of multiphoton microscopy, the optical clearing of tissue and its application to pathology. He served on the faculty of Yale University from 2004 to 2014, after which he co-founded Applikate. Michael holds 20 granted U.S. Patents, authored 32 publications, and raised more than $6.3 million in research support between 2007 and the present.
Prior to joining Yale,  Michael was a Research Associate in Applied and Engineering Physics at Cornell University, where he worked with Prof. Watt Webb and co-invented zero-mode waveguides for single molecule DNA sequencing, the technological foundation of Pacific Biosciences, Inc.
Icon-linkedin-1 Icon-bookmark
Yale University School of Medicine
 
 

Richard Torres, M.D.

Founder, Co-CEO
Rick Torres is a pathologist and biomedical engineer with expertise in medical laboratory instrumentation. He is board certified in Clinical and Anatomic Pathology and has worked as an independent consultant on commercial medical diagnostic devices. His clinical interests include flow cytometry, pathology informatics, and next generation sequencing for hematologic malignancies, having served as medical director of clinical chemistry, hematology, immunology, and flow cytometry laboratories. Rick Torres co-invented the novel histology techniques and devices developed by Applikate, served on the faculty of Yale University, co-founded the company, serves as Co-CEO, and holds several seminal patents. He maintains an adjunct appointment at Yale where he continues to perform part-time clinical interpretative work.
Icon-linkedin-1 Icon-bookmark Icon-monitor